Saturday
09.21.2019
6:31 AM
Login form
Search
Calendar
Entries archive

My site

Main » 2018 » October » 27

MiRIS Project investigates energy storage, PV, and microgrid integration and optimization


SERAING, Belgium-Friday 26 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- CMI Energy, part of CMI Group, will be inaugurating Europe's largest industrial energy storage facility on October 26, 2018. The MiRIS (Micro Réseau Intégré Seraing) energy storage pilot plant consists of energy storage and PV integrated with a microgrid. The purpose of the full-scale pilot project is to demonstrate advanced integration of intermittent renewable energy resources with battery-based energy storage to produce a fully dispatchable renewable energy resource. MiRIS is located at the CMI Group’s international headquarters, located in Seraing (Belgium).

Jean-Michel Gheeraerdts, President of CMI Energy, when announcing the MiRIS project said, “We now have ways to use green energy sources that eradicate their major flaw: intermittent production. Energy storage and manag ... Read more »

Views: 54 | Added by: africanewsline | Date: 10.27.2018

NEW YORK & LONDON-Friday 26 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Moody’s Corporation (NYSE:MCO) today announced the selection of its inaugural list of partners for Reshape TomorrowTM, its innovative, global program to help owners of small and growing business overcome the challenges of expanding their enterprises.

Moody’s has selected a network of six partner organizations and programs, supported by grants from Moody’s Foundation, that focus on empowering entrepreneurs — especially women and members of untapped communities — by helping to provide the expertise and tools needed to navigate the credit process and thrive. Over 50 organizations from around the world applied to participate in the program, which is a key part of Moody’s global Corporate Social Responsibility (CSR) initiative.

“Moody’s is proud to partner with these innovative organizations as the core of Reshape Tomorrow. Together, we aim ... Read more »

Views: 48 | Added by: africanewsline | Date: 10.27.2018 | Comments (0)

DUBLIN-Friday 26 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Arch Mortgage Insurance dac (“Arch”) today announced it has completed a capital relief transaction on a €3 billion subset of a residential mortgage loan portfolio of ING DiBa A.G., a wholly owned subsidiary of ING Bank N.V. The deal is the first of its kind in the European mortgage market and represents a valuable new tool for financial institutions in managing their regulatory capital.

“Arch is delighted to complete a transaction that supports mortgage lending in Germany,” said Beau Franklin, President and Chief Executive Officer of Arch’s International Mortgage Group. “Arch is committed to bringing innovative products to market and taking a leadership role in providing capital relief solutions on residential mortgage loans globally.”

About Arch Mortgage Insurance dac

Arch Mortgage Insurance dac is based in Dublin and provides efficient and i ... Read more »

Views: 30 | Added by: africa-live | Date: 10.27.2018 | Comments (0)

HEMEL HEMPSTEAD, England-Monday 22 October 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.1

The outline of the new proposed guidelines was presented on 19th October at the annual ESMO 2018 Congress in Munich, Germany, and indicated that tivozanib will be included as a first-line treatment recommendation for aRCC clear cell histology patients. The update will position tivozanib as a treatment standard for good (or favourable) risk patients with a Class IIa recommendation, and a treatment option for intermediate risk patients with a Class IIb recommendation.1

The indication of inclusion of tivozanib in the ESMO guidelines follows the grant of a European Commission (EC) licence in August 2017 for ... Read more »

Views: 32 | Added by: africanewsline | Date: 10.27.2018

• Third quarter revenue at €727 million, (3%) lower at constant exchange rates

... Read more »

Views: 68 | Added by: africa-live | Date: 10.27.2018 | Comments (0)

PARIS-Friday 26 October 2018 [ AETOS Wire ]
(BUSINESS WIRE)-- On the occasion of Euronaval 2018, CNIM announces the launch of two families of crafts: the Landing Crafts Assault or LCA, for Ground Forces projection; and Landing Crafts X-missions or LCX, a versatile, fast offshore vessel designed to fulfill Naval Forces’ needs.

CNIM designed the new generation of vessels to provide operational versatility for a mothership working alongside the L-CAT® Ship-to-Shore.

    The LCA, operational support for Ground Forces

Robust, reliable, roll-on roll-off and travelling at 13 knots with a 65-tons payload (80 tons maximum), the LCA is designed to transfer equipment and people ashore efficiently from the mothership (NATO or Makassar-class).

Like all CNIM amphibious crafts, the LCA can beach in very shallow water (~1m). With excellent mobility and maneuverability, the LCA lands and picks up Ground Forces in record time during amphi ... Read more »

Views: 31 | Added by: africa-live | Date: 10.27.2018

Additional subgroup analysis shows subcutaneous formulation of vedolizumab achieves significantly higher clinical remission rates to placebo in anti-TNFα-naïve patients


OSAKA, Japan-Monday 22 October 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. At week 52, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** compared to patients receiving placebo (46.2% vs. 14.3%; p<0.001). A similar rate of clinical remission was observed ... Read more »

Views: 32 | Added by: africanewsline | Date: 10.27.2018